News Releases

Strong foundations laid ahead of planned regulatory submissions in 2023 LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care,

Data from the study to support regulatory submissions on track for 2023 Participation from distinguished EU principal investigators provides significant endorsement for DeepView™    LONDON, U.K. AND DALLAS, TX, U.S  -Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with

LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that, as at the date of this announcement, there are 136,201,515

DeepView® accuracy increases to 86% in diagnosis of DFU healing potential on day one LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in

Unaudited cash, revenue and loss for the year expected to be ahead of expectations LONDON, U.K AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment

Accomplished technology executive and innovator Dr. Niko Pagoulatos joins Spectral MD LONDON, U.K AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for rapid and accurate treatment decisions in wound

LONDON, U.K AND DALLAS, TX, U.S.  Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, announces that a block listing application (“Block Listing”) has been made to the London

Spectral MD expected to exceed full year market expectations for revenue, margins, and EBITDA Burn and Diabetic Foot Ulcer (“DFU”) clinical studies remain on track LONDON, U.K AND DALLAS, TX, U.S.  Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms

LONDON, U.K AND DALLAS, TX, U.S.  Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that Erich Spangenberg, Non-Executive Director, has elected to

LONDON, U.K AND DALLAS, TX, U.S.  Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the exercise of options by certain employees of the Company (the